AstraZeneca (AZN) CEO Brennan to Retire
Tweet
Share
E-mailGet Alerts AZN Hot Sheet
Join SI Premium – FREE
AstraZeneca (NYSE: AZN) announced that Chief Executive Officer and Board member, David Brennan has decided to retire.
Following David’s decision, the Board has asked Executive Director and Chief Financial Officer Simon Lowth to act as interim Chief Executive Officer from 1 June 2012 until a permanent successor is in place. Julie Brown, Vice President Group Finance, will become interim Chief Financial Officer on the same date. David Brennan will retire from AstraZeneca and relinquish his Board responsibilities on 1 June 2012.
Following David’s decision, the Board has asked Executive Director and Chief Financial Officer Simon Lowth to act as interim Chief Executive Officer from 1 June 2012 until a permanent successor is in place. Julie Brown, Vice President Group Finance, will become interim Chief Financial Officer on the same date. David Brennan will retire from AstraZeneca and relinquish his Board responsibilities on 1 June 2012.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
- Illumisoft names new CEO, lists on OTCQB, plans debt settlement
- Baxter names John Rogers as CFO, effective October 2026
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
